Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion

Clinical and Experimental Nephrology

Volumn 16, Issue 5, 2012, Pages 659-671

  Suzuki, Kenshi ^a  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

AL amyloidosis; ASCT; Multiple myeloma; Renal insufficiency

Indexed keywords

BENCE JONES PROTEIN; BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; IMMUNOGLOBULIN D; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; M PROTEIN; MELPHALAN; PREDNISOLONE; PREDNISONE; SERUM ALBUMIN; THALIDOMIDE;

AL AMYLOIDOSIS; AMYLOIDOSIS; ASTHENIA; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CONSTIPATION; CREATININE BLOOD LEVEL; CYCLIN D1 GENE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPROTEINEMIA; FATIGUE; GENE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPOALBUMINEMIA; INTERSTITIAL LUNG DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LONG TERM SURVIVAL; LUNG DISEASE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; NEPHROTOXICITY; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SECOND CANCER; SOMNOLENCE; THROMBOCYTOPENIA; UPREGULATION;

AGED; AMYLOIDOSIS; BENCE JONES PROTEIN; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; HUMANS; KIDNEY; MELPHALAN; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; PYRAZINES; RENAL INSUFFICIENCY; THALIDOMIDE;

EID: 84868345301     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0684-5     Document Type: Review

References (49)

1. Dispenzieri A, et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Riskadapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323-41.
2. Bergsagel DE, et al. Myeloma proteins and the clinical response to melphalan therapy. Science. 1965;148(3668):376-7.
3. Salmon SC, et al. Intermittent high dose prednisone therapy for multiple myeloma. Cancer Chemother Rep. 1967;51:179-87.
4. Alexanian R, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208(9):1680-5.
5. Kyle RA, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002; 346:564-9.
6. San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359(9):906-17.
7. Kumar SK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-20.
8. Hideshima T, et al. Intracellular protein degradation and its therapeutic implications. Clin Cancer Res. 2005;11(24 Pt 1): 8530-3.
9. Fayers PM, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118: 1239-47.
10. Richardson PG, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24): 2487-98.
11. San Miguel JF, et al. ASH2011. http://myeloma.org/pdfs/ASH2011- San%20Miguel-3619.pdf.
12. Suzuki K. Discovery research on the effects of giving continuity to the administration of bortezomib in maintenance therapy to target of relapsed and refractory multiple myeloma. J New Rem Clin. 2012;61:1259-69.
13. Durie BGM, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-73.
14. Niesvizky R, et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008;143(1):46-53.
15. Harousseau JL, et al. The role of complete response in multiple myeloma. Blood. 2009;114(15):3139-46.
16. Chanan-Khan A, et al. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28(15):2612-24.
17. Palumbo A, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trial. Blood. 2008;112(8):3107-14.
18. Facon T, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594): 1209-18.
19. Hulin C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22): 3664-70.
20. Rajkmar SV, et al. ASH 2008 joint ASH/ASCO symposium.
21. Dimopoulos MA, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5(2):112-7.
22. Garcia-Sanz R, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia. 2004;18(4): 856-63.
23. Kyriakou C, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol. 2005;129(6): 763-70.
24. Palumbo A, et al. Multiple myeloma. N Engl J Med. 2011; 364(11):1046-60.
25. Ladetto M, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12):2077-84.
26. Cave M, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012; 120:9-19.
27. Abderrahman A, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood. 2008;111:1805-10.
28. Singhal S, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-71.
29. Suzuki K, et al. Maintenance therapy of bortezomib-dexa (BzDx) for multiple myeloma. Clin Hematol. 2010;51(9):1181.
30. Attal M, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19): 1782-91.
31. Palumbo A, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19): 1759-69.
32. Reece DE, et al. ASH2010 Poster #1877.
33. Abe Y, Suzuki K, et al. Abstract PS-2-26 (1264) 498. Japan Society of Hematology; 2011.
34. Treatment guidance of multiple myeloma. 2nd ed. Japanese Society of Myeloma; 2008.
35. Blade J, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889-93.
36. Roussou M, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res. 2010;34:1395-7.
37. Dimopoulos M, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer. 2010;116: 3807-14.
38. Revlimid Capsules Package Insert. http://www.revlimid-japan.jp/ professional/product/pdf/pi/pi-rev-201201.pdf.
39. Dimopoulos M, et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol. 2010;85:1-5.
40. Klein U, et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol. 2011;90:429-39.
41. La Rubia DE, et al. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. Eur J Haematol. 2011;85:363-5.
42. Dimopoulos M, et al. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia. 2011;25:749-60.
43. Kumar S, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116:5126-9.
44. Dispenzieri A, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103:3960.
45. Sanchorawala V, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110:3561.
46. Skinner M, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85.
47. Merlini G, et al. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011;29:1924-33.
48. Cibelia MT, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118:4346-52.
49. Madan B, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119:1117-22.